INCA-6
(Synonyms: Triptycene-1,4-quinone) 目录号 : GC16117A cell-permeant inhibitor of NFAT signaling
Cas No.:3519-82-2
Sample solution is provided at 25 µL, 10mM.
INCA-6 is a selective inhibitor of transcription factor NFAT with Kd value of 0.8 mM in vitro[1].
NFAT (Nuclear factor of activated T-cells) is a general name which is applied to a family of transcription factors that are important in immune response. They are expressed in most immune system cells. Calcium signaling plays an important role in NFAT activation. Calmodulin activates calcineurin (CN) which is a serine/threonine phosphatase, then dephosphorylates the amino termini of NFAT proteins resulting a conformational change. NFAT will transport into nuclear. NFAT proteins will cooperate with other nuclear resident transcription factors due to that they have weak DNA-binding capacity. NFAT proteins have weak DNA-binding capacity NFAT transcription factors are specifically implicated in the process of cell motility and are related to breast cancer.[2]
INCA-6 treatment significant blocked translocation of nuclear factor of activated T-cells c1. INCA-6 effectively blocked the stimulation of vascular endothelial growth factor stimulation at 1.0 μM. INCA-6 significantly tube formation at 1.0μM in human retinal microvascular endothelial cells[1]. INCA-6 at 50 μM inhibited ATP-induced activation of NFATc1 in MG-5 cells.[3] In BV-2 cells, INCA-6 at 10
μM significantly inhibited ATP-induced CXCL2 expression.[4] INCA-6 reversed the proliferative effect of E2.[5]
References:
[1]. Bretz CA, Savage S, Capozzi M, Penn JS: The role of the NFAT signaling pathway in retinal neovascularization. Invest Ophthalmol Vis Sci 2013, 54(10):7020-7027.
[2]. Crabtree GR, Olson EN: NFAT signaling: choreographing the social lives of cells. Cell 2002, 109 Suppl:S67-79.
[3]. Kataoka A, Tozaki-Saitoh H, Koga Y, Tsuda M, Inoue K: Activation of P2X7 receptors induces CCL3 production in microglial cells through transcription factor NFAT. J Neurochem 2009, 108(1):115-125.
[4]. Shiratori M, Tozaki-Saitoh H, Yoshitake M, Tsuda M, Inoue K: P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways. J Neurochem 2010, 114(3):810-819.
[5]. Wong CK, So WY, Law SK, Leung FP, Yau KL, Yao X, Huang Y, Li X, Tsang SY: Estrogen controls embryonic stem cell proliferation via store-operated calcium entry and the nuclear factor of activated T-cells (NFAT). J Cell Physiol 2012, 227(6):2519-2530.
Cas No. | 3519-82-2 | SDF | |
别名 | Triptycene-1,4-quinone | ||
化学名 | (9s,10s)-9,10-[1,2]benzenoanthracene-13,16(9H,10H)-dione | ||
Canonical SMILES | O=C(C=CC1=O)C2=C1[C@@H]3C(C=CC=C4)=C4[C@H]2C5=C3C=CC=C5 | ||
分子式 | C20H12O2 | 分子量 | 284.31 |
溶解度 | DMF: 20 mg/mL,DMSO: 2 mg/mL | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.5173 mL | 17.5864 mL | 35.1729 mL |
5 mM | 0.7035 mL | 3.5173 mL | 7.0346 mL |
10 mM | 0.3517 mL | 1.7586 mL | 3.5173 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet